[ad_1]
“Following new reports of cerebrovascular thrombosis vaccination in Germany and Europe, the PEI (Paul Erhlich Institute) believes that more research is needed,” the Health Ministry said, citing the country’s authority responsible for oversight of vaccination. .
“The European Medicines Agency (EMA) will decide whether and how the new findings will affect the approval of this vaccine,” the ministry added.
Italians and French joined
Italy and France said Monday they were following the lead of other European countries and stopping vaccines against the coronavirus vaccine, developed by AstraZeneca and the University of Oxford, following fears that the drug could stimulate blood clots.
A report from the Italian Medicines Agency states: “The AIFA has decided to extend the ban on the use of the AstraZeneca vaccine against COVID-19 as a preventive and temporary measure, pending the rulings of the European Medicines Agency (EMA).”
It also claims that this decision is in line with similar steps in other European countries.
French President Emmanuel Macron has also announced that vaccination with AstraZeneca is being stopped in his country and that EVA conclusions are awaited.
“A decision has been made … to suspend the use of AstraZeneca as a precaution, in the hope that we can resume it soon if the EVA evaluation allows it,” Macron told a press conference. He added that an EVA decision is expected on Tuesday afternoon.
Several European countries, including Ireland and the Netherlands, froze the use of AstraZeneca, developed jointly with the University of Oxford, last week.
The UK and Sweden-based company and Oxford University said there was no link between the vaccine and increased blood clotting.
AstraZeneca reported that 15 cases of deep vein thrombosis (DVT) and 22 cases of pulmonary embolism were reported in vaccinated people. According to the company, this figure is “much lower than would be expected under natural conditions in the general population” in terms of total injections.
The vaccine is widely used for vaccination in Britain, but the European Union has experienced an interruption in the supply of AstraZeneca.
